title: Glutamate-dopamine crosstalk in the rat prefrontal cortex is modulated by Alpha7 nicotinic receptors and potentiated by PNU-120596.
abstract: The aim of this study was to explore the modulation by alpha7 nicotinic receptors (nAChRs) of dopamine and glutamate release in the rat prefrontal cortex where these receptors are implicated in attentional processes and are therapeutic targets for cognitive deficits. The presence of presynaptic alpha7 nAChRs on glutamate terminals is supported by the ability of the subtype-selective agonist Compound A to evoke [(3)H]D-aspartate release from synaptosomes: This response was potentiated by the selective allosteric potentiator PNU-120596 and blocked by alphabungarotoxin. Compound A also evoked dopamine overflow in the prefrontal cortex in vivo, and this was potentiated by PNU-120596. alpha7 nAChR-evoked [(3)H]dopamine release from tissue prisms in vitro was blocked by antagonists of NMDA and AMPA receptors. These data are consistent with a model in which alpha7 nAChRs present on glutamate terminals increase glutamate release that (1) contributes to presynaptic facilitation and synaptic plasticity and (2) co-ordinately enhances dopamine release from neighbouring boutons.
authors.affiliation: Department of Biology & Biochemistry, University of Bath, Bath, BA2 7AY, UK.
authors.forename: Phil D
authors.initials: PD
authors.lastname: Livingstone
authors.forename: Jane A
authors.initials: JA
authors.lastname: Dickinson
authors.forename: Jayaraman
authors.initials: J
authors.lastname: Srinivasan
authors.forename: James N C
authors.initials: JN
authors.lastname: Kew
authors.forename: Susan
authors.initials: S
authors.lastname: Wonnacott
mesh_terms: D000109:Acetylcholine / Q000378:metabolism; D000818:Animals; D001224:Aspartic Acid / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D045604:Extracellular Fluid / Q000187:drug effects / Q000378:metabolism; D005973:Glutamine / Q000378:metabolism*; D007555:Isoxazoles / Q000494:pharmacology; D017551:Microdialysis; D009473:Neuronal Plasticity / Q000187:drug effects / Q000502:physiology; D018722:Nicotinic Agonists / Q000494:pharmacology; D018733:Nicotinic Antagonists / Q000494:pharmacology; D010671:Phenylurea Compounds / Q000494:pharmacology; D017397:Prefrontal Cortex / Q000187:drug effects* / Q000378:metabolism*; D017729:Presynaptic Terminals / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D011978:Receptors, Nicotinic / Q000187:drug effects* / Q000378:metabolism*; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology; D013574:Synaptosomes; D064569:alpha7 Nicotinic Acetylcholine Receptor
chemical_list: C508388:1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)urea; C579165:Chrna7 protein, rat; D018691:Excitatory Amino Acid Antagonists; D007555:Isoxazoles; D018722:Nicotinic Agonists; D018733:Nicotinic Antagonists; D010671:Phenylurea Compounds; D011978:Receptors, Nicotinic; D064569:alpha7 Nicotinic Acetylcholine Receptor; D005973:Glutamine; D001224:Aspartic Acid; D000109:Acetylcholine; D004298:Dopamine
references.citation: J Neurochem. 2007 Feb;100(4):1089-96
references.pmid: 17181555
references.citation: Cereb Cortex. 2007 Sep;17 Suppl 1:i151-60
references.pmid: 17725997
references.citation: Psychopharmacology (Berl). 2006 Mar;184(3-4):292-305
references.pmid: 16001117
references.citation: Mol Pharmacol. 2008 Aug;74(2):348-59
references.pmid: 18445710
references.citation: Prog Neurobiol. 2007 Oct;83(2):69-91
references.pmid: 17681661
references.citation: J Neurosci. 2005 Apr 27;25(17):4396-405
references.pmid: 15858066
references.citation: J Neurochem. 2002 Mar;80(6):1071-8
references.pmid: 11953457
references.citation: Mol Pharmacol. 2000 Aug;58(2):312-8
references.pmid: 10908298
references.citation: Eur J Neurosci. 1997 Dec;9(12):2734-42
references.pmid: 9517478
references.citation: Curr Med Chem. 2008;15(28):2921-32
references.pmid: 19075644
references.citation: Mol Pharmacol. 2006 Feb;69(2):618-28
references.pmid: 16269536
references.citation: Trends Pharmacol Sci. 2004 Jun;25(6):317-24
references.pmid: 15165747
references.citation: J Neurochem. 1998 Oct;71(4):1443-9
references.pmid: 9751176
references.citation: Neuropharmacology. 2005 Jul;49(1):59-72
references.pmid: 15992581
references.citation: Neurochem Res. 2000 Oct;25(9-10):1265-74
references.pmid: 11059801
references.citation: Eur J Neurosci. 2009 Feb;29(3):539-50
references.pmid: 19187266
references.citation: Ann N Y Acad Sci. 2003 Nov;1003:36-52
references.pmid: 14684434
references.citation: J Neurochem. 2009 Jan;108(2):408-16
references.pmid: 19046354
references.citation: Neuropharmacology. 2007 Jun;52(8):1641-9
references.pmid: 17482650
references.citation: Neuron. 2002 Oct 10;36(2):241-63
references.pmid: 12383780